Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Autologous stem cell therapy - Takeda

Drug Profile

Autologous stem cell therapy - Takeda

Alternative Names: Adult stem cell therapy for chronic myocardial ischaemia - Shire; CD34+ autologous stem cell therapy - Shire/Caladarius Biosciences; CD34+ cell therapy - Shire/Caladarius Biosciences

Latest Information Update: 02 Aug 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Baxter Healthcare Corporation
  • Developer Baxter Healthcare Corporation; Northwestern University; Takeda
  • Class Cardiovascular therapies; Stem cell therapies
  • Mechanism of Action Angiogenesis inducing agents; Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • No development reported Myocardial ischaemia; Peripheral vascular disorders

Most Recent Events

  • 02 Aug 2019 No development reported - Phase-III for Myocardial ischaemia in USA (Intracoronary) (NCT01508910)
  • 08 Jan 2019 Shire has been acquired and merged into Takeda
  • 19 Jun 2018 Autologous stem cell therapy receives regenerative medicine advanced therapy (RMAT) status for Chronic myocardial ischaemia (Refractory angina) in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top